Review



mouse anti vecadherin  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems mouse anti vecadherin
    Mouse Anti Vecadherin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 70 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ve+cadherin/Human+VE-Cadherin+Antibody/10__1096_slash_fj__202600727r-78-28-33
    Average 93 stars, based on 70 article reviews
    mouse anti vecadherin - by Bioz Stars, 2026-10
    93/100 stars

    Images

    Related Articles

    Incubation:

    Article Title: Endothelial IRE1 signaling maintains blood-brain barrier integrity and limits neuroinflammation after traumatic brain injury.
    Article Snippet: The brains were then cryoprotected in 30% sucrose in phosphate buffer at 4 °C for 2 days and were coronally sectioned at 30 μm thickness using a cryostat (Leica Biosystems, Wetzlar, Germany). .. Sections were blocked with 3% bovine serum albumin in 0.3% Triton X-100 for 1 h at room temperature and were incubated overnight at 4 °C with the following primary antibodies: anti-GFP (598, MBL, Tokyo, Japan; RRID:AB_591819, 1:1000), anti-CD31 (550274, BD Pharmingen, Franklin Lakes, NJ; RRID:AB_393571, 1:100), anti-VE-cadherin (AF1002, R&D Systems, Abingdon, UK; RRID:AB_2077789, 1:100), antiCXCL10 (AF-466-NA, R&D Systems; RRID:AB_2292487, 1:200), anti-CD45 (550539, BD Pharmingen; RRID:AB_2174426, 1:200), anti-Laminin (L9393, Sigma, St. Louis, MO; RRID:AB_477163, 1:4000), anti-NeuN (24307, Cell Signaling Technology, Danvers, MA, USA; RRID:AB_2651140), and anti-Iba1 (ab107159, Abcam, Cambridge, UK; RRID:AB_10972670, 1:1000; and 019- 19741, Wako; RRID:AB_839504, 1:500). anti-ERG (ab92513, Abcam, Cambridge, UK; RRID:AB_2630401, 1:800), anti-SMI31 (NE1022, Millipore; RRID:AB_2043448, 1:800), anti-IRE1α (NB100-2323, Novus; RRID: AB_10145203, 1:500), anti-p62 (018-22141, Wako; RRID:AB_10658438, 1:500), Secondary antibodies conjugated to Alexa Fluor 488 or Cy3 were used for fluorescence detection. ..

    Article Title: Disturbed flow induces reprogramming of endothelial cells to immune-like and foam cells under hypercholesterolaemia during atherogenesis
    Article Snippet: Tissue sections were deparaffinized and subsequently subjected to antigen retrieval, followed by permeabilization and blocking in PBST supplemented with 0.1% Triton X-100 (Sigma-Aldrich #X100, St. Louis, MO) and 5% bovine serum albumin (Sigma–Aldrich, St. Louis, MO, #A7906). .. Tissue sections were concurrently incubated with Anti-VE-Cadherin (R&D Systems, Minneapolis, MN, AF938) and Anti-FIRE marker (as described in Supplementary material online , Table S3 ) at 4°C overnight, followed by Alexa Fluor-568 and −647 (Thermo Fisher Scientific, Waltham, MA, 1:500) secondary antibody for 1 h at room temperature. .. Nuclei were counterstained using Fluoroshield with DAPI (Sigma Aldrich, St. Louis, MO, #F6057).

    Article Title: FGFR1/YAP1 signaling in endothelial cells drives renal fibrosis and offers a therapeutic target
    Article Snippet: .. Both types of sections were incubated overnight at 4 °C with the following primary antibodies: anti-YAP1 (1:100; Abcam, # AB205270 ), anti-VE-cadherin (1:100; R&D Systems, #AF1002), anti-FGFR1 (1:100; Cell Signaling Technology, #9740S), anti-Fibronectin (1:200; Proteintech, #15613-1-AP), anti-Desmin (1:200; Abcam, #AB15200), anti-α-SMA (1:200; Proteintech, #14395-1-AP), and anti-Collagen I (1:200; Proteintech, #14695-1-AP). .. After washing with PBS, the sections were incubated with species-matched Alexa Fluor-conjugated secondary antibodies (1:500; Abcam, # AB150157 , # AB150074 ) for 1 h at room temperature in the dark.

    Article Title: Endothelial IRE1 signaling maintains blood–brain barrier integrity and limits neuroinflammation after traumatic brain injury
    Article Snippet: The brains were then cryoprotected in 30% sucrose in phosphate buffer at 4 °C for 2 days and were coronally sectioned at 30 μm thickness using a cryostat (Leica Biosystems, Wetzlar, Germany). .. Sections were blocked with 3% bovine serum albumin in 0.3% Triton X-100 for 1 h at room temperature and were incubated overnight at 4 °C with the following primary antibodies: anti-GFP (598, MBL, Tokyo, Japan; RRID:AB_591819, 1:1000), anti-CD31 (550274, BD Pharmingen, Franklin Lakes, NJ; RRID:AB_393571, 1:100), anti-VE-cadherin (AF1002, R&D Systems, Abingdon, UK; RRID:AB_2077789, 1:100), anti-CXCL10 (AF-466-NA, R&D Systems; RRID:AB_2292487, 1:200), anti-CD45 (550539, BD Pharmingen; RRID:AB_2174426, 1:200), anti-Laminin (L9393, Sigma, St. Louis, MO; RRID:AB_477163, 1:4000), anti-NeuN (24307, Cell Signaling Technology, Danvers, MA, USA; RRID:AB_2651140), and anti-Iba1 (ab107159, Abcam, Cambridge, UK; RRID:AB_10972670, 1:1000; and 019-19741, Wako; RRID:AB_839504, 1:500). anti-ERG (ab92513, Abcam, Cambridge, UK; RRID:AB_2630401, 1:800), anti-SMI31 (NE1022, Millipore; RRID:AB_2043448, 1:800), anti-IRE1α (NB100-2323, Novus; RRID: AB_10145203, 1:500), anti-p62 (018-22141, Wako; RRID:AB_10658438, 1:500), Secondary antibodies conjugated to Alexa Fluor 488 or Cy3 were used for fluorescence detection. ..

    Fluorescence:

    Article Title: Endothelial IRE1 signaling maintains blood-brain barrier integrity and limits neuroinflammation after traumatic brain injury.
    Article Snippet: The brains were then cryoprotected in 30% sucrose in phosphate buffer at 4 °C for 2 days and were coronally sectioned at 30 μm thickness using a cryostat (Leica Biosystems, Wetzlar, Germany). .. Sections were blocked with 3% bovine serum albumin in 0.3% Triton X-100 for 1 h at room temperature and were incubated overnight at 4 °C with the following primary antibodies: anti-GFP (598, MBL, Tokyo, Japan; RRID:AB_591819, 1:1000), anti-CD31 (550274, BD Pharmingen, Franklin Lakes, NJ; RRID:AB_393571, 1:100), anti-VE-cadherin (AF1002, R&D Systems, Abingdon, UK; RRID:AB_2077789, 1:100), antiCXCL10 (AF-466-NA, R&D Systems; RRID:AB_2292487, 1:200), anti-CD45 (550539, BD Pharmingen; RRID:AB_2174426, 1:200), anti-Laminin (L9393, Sigma, St. Louis, MO; RRID:AB_477163, 1:4000), anti-NeuN (24307, Cell Signaling Technology, Danvers, MA, USA; RRID:AB_2651140), and anti-Iba1 (ab107159, Abcam, Cambridge, UK; RRID:AB_10972670, 1:1000; and 019- 19741, Wako; RRID:AB_839504, 1:500). anti-ERG (ab92513, Abcam, Cambridge, UK; RRID:AB_2630401, 1:800), anti-SMI31 (NE1022, Millipore; RRID:AB_2043448, 1:800), anti-IRE1α (NB100-2323, Novus; RRID: AB_10145203, 1:500), anti-p62 (018-22141, Wako; RRID:AB_10658438, 1:500), Secondary antibodies conjugated to Alexa Fluor 488 or Cy3 were used for fluorescence detection. ..

    Article Title: Endothelial IRE1 signaling maintains blood–brain barrier integrity and limits neuroinflammation after traumatic brain injury
    Article Snippet: The brains were then cryoprotected in 30% sucrose in phosphate buffer at 4 °C for 2 days and were coronally sectioned at 30 μm thickness using a cryostat (Leica Biosystems, Wetzlar, Germany). .. Sections were blocked with 3% bovine serum albumin in 0.3% Triton X-100 for 1 h at room temperature and were incubated overnight at 4 °C with the following primary antibodies: anti-GFP (598, MBL, Tokyo, Japan; RRID:AB_591819, 1:1000), anti-CD31 (550274, BD Pharmingen, Franklin Lakes, NJ; RRID:AB_393571, 1:100), anti-VE-cadherin (AF1002, R&D Systems, Abingdon, UK; RRID:AB_2077789, 1:100), anti-CXCL10 (AF-466-NA, R&D Systems; RRID:AB_2292487, 1:200), anti-CD45 (550539, BD Pharmingen; RRID:AB_2174426, 1:200), anti-Laminin (L9393, Sigma, St. Louis, MO; RRID:AB_477163, 1:4000), anti-NeuN (24307, Cell Signaling Technology, Danvers, MA, USA; RRID:AB_2651140), and anti-Iba1 (ab107159, Abcam, Cambridge, UK; RRID:AB_10972670, 1:1000; and 019-19741, Wako; RRID:AB_839504, 1:500). anti-ERG (ab92513, Abcam, Cambridge, UK; RRID:AB_2630401, 1:800), anti-SMI31 (NE1022, Millipore; RRID:AB_2043448, 1:800), anti-IRE1α (NB100-2323, Novus; RRID: AB_10145203, 1:500), anti-p62 (018-22141, Wako; RRID:AB_10658438, 1:500), Secondary antibodies conjugated to Alexa Fluor 488 or Cy3 were used for fluorescence detection. ..

    Immunostaining:

    Article Title: Exercise‐Induced Cardiac Lymphatic Remodeling Mitigates Inflammation in the Aging Heart
    Article Snippet: .. Immunostaining was performed using primary antibodies, including anti‐LYVE‐1 (1:100, #11–034, Angiobio), anti‐LYVE‐1 (1:100, #MAB2125‐100, R&D SYSTEMS), anti‐VEGFR3 (1:100, #AF743, R&D SYSTEMS), anti‐VE‐Cadherin (1:100, # AF1002, R&D SYSTEMS), anti‐Ki‐67 (1:50, #14–5698‐82, eBioscience), anti‐CD31 (1:100, #557355, BD Pharmingen), anti‐CD3 (1:100, #100236, BioLegend), anti‐CD68 (1:100, #MCA1957, Biocompare), anti‐CD206 (1:100, #PA5‐46994, Invitrogen), anti‐ACTN2 (1:100, #14221‐1‐AP, Proteintech), anti‐COL1 (1:100, #NB600‐450, Novus Biologicals), anti‐Perilipin1 (1:100, #9349S, Cell Signaling), and anti‐WGA (1:200, W11261 , Invitrogen). .. Secondary antibodies conjugated with Alexa Fluor 488, 594, and 647 were purchased from Jackson ImmunoResearch.

    Marker:

    Article Title: Disturbed flow induces reprogramming of endothelial cells to immune-like and foam cells under hypercholesterolaemia during atherogenesis
    Article Snippet: Tissue sections were deparaffinized and subsequently subjected to antigen retrieval, followed by permeabilization and blocking in PBST supplemented with 0.1% Triton X-100 (Sigma-Aldrich #X100, St. Louis, MO) and 5% bovine serum albumin (Sigma–Aldrich, St. Louis, MO, #A7906). .. Tissue sections were concurrently incubated with Anti-VE-Cadherin (R&D Systems, Minneapolis, MN, AF938) and Anti-FIRE marker (as described in Supplementary material online , Table S3 ) at 4°C overnight, followed by Alexa Fluor-568 and −647 (Thermo Fisher Scientific, Waltham, MA, 1:500) secondary antibody for 1 h at room temperature. .. Nuclei were counterstained using Fluoroshield with DAPI (Sigma Aldrich, St. Louis, MO, #F6057).



    Similar Products

    93
    Miltenyi Biotec anti cd144
    Anti Cd144, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ve+cadherin/CD144+(VE-Cadherin)+Antibody%2C+anti-mouse%2C+REAfinity/pm42831433-183-16-17
    Average 93 stars, based on 1 article reviews
    anti cd144 - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology mouse anti ve cadherin
    Mouse Anti Ve Cadherin, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ve+cadherin/VE-cadherin+Antibody/pmc13657077-104-52-55
    Average 96 stars, based on 1 article reviews
    mouse anti ve cadherin - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Proteintech ve cadherin
    circIdh2 attenuated TGF‐ β 1–induced EndMT changes in rEPCs. rEPCs were treated with or without TGF‐ β 1 (5 ng/mL) for 7 days, and then transfected with PCDH‐NC or PCDH‐circIdh2. (A) qRT‐PCR analysis of circIdh2 expression after transfection for 24 h. (B) Western blot analysis of EndMT‐related proteins <t>(VE‐cadherin,</t> vimentin, and N‐cadherin) after transfection for 48 h. (C) Transwell assay was performed to assess cell migration after transfection for 24 h. (D) Representative scratch wound healing images at 0, 24, and 48 h. Scale bars, 200 μ m. (E) Quantification of relative wound width (% of PCDH‐NC at 0 h). Data are mean ± SD; n = 3 independent biological experiments; one‐way ANOVA; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.
    Ve Cadherin, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ve+cadherin/CDH5+Antibody/pmc13647212-116-7-10
    Average 96 stars, based on 1 article reviews
    ve cadherin - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology anti ve cadherin
    circIdh2 attenuated TGF‐ β 1–induced EndMT changes in rEPCs. rEPCs were treated with or without TGF‐ β 1 (5 ng/mL) for 7 days, and then transfected with PCDH‐NC or PCDH‐circIdh2. (A) qRT‐PCR analysis of circIdh2 expression after transfection for 24 h. (B) Western blot analysis of EndMT‐related proteins <t>(VE‐cadherin,</t> vimentin, and N‐cadherin) after transfection for 48 h. (C) Transwell assay was performed to assess cell migration after transfection for 24 h. (D) Representative scratch wound healing images at 0, 24, and 48 h. Scale bars, 200 μ m. (E) Quantification of relative wound width (% of PCDH‐NC at 0 h). Data are mean ± SD; n = 3 independent biological experiments; one‐way ANOVA; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.
    Anti Ve Cadherin, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ve+cadherin/VE-cadherin+Antibody/pmc13643346-256-5-6
    Average 96 stars, based on 1 article reviews
    anti ve cadherin - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Proteintech anti ve cadherin rabbit antibody
    circIdh2 attenuated TGF‐ β 1–induced EndMT changes in rEPCs. rEPCs were treated with or without TGF‐ β 1 (5 ng/mL) for 7 days, and then transfected with PCDH‐NC or PCDH‐circIdh2. (A) qRT‐PCR analysis of circIdh2 expression after transfection for 24 h. (B) Western blot analysis of EndMT‐related proteins <t>(VE‐cadherin,</t> vimentin, and N‐cadherin) after transfection for 48 h. (C) Transwell assay was performed to assess cell migration after transfection for 24 h. (D) Representative scratch wound healing images at 0, 24, and 48 h. Scale bars, 200 μ m. (E) Quantification of relative wound width (% of PCDH‐NC at 0 h). Data are mean ± SD; n = 3 independent biological experiments; one‐way ANOVA; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.
    Anti Ve Cadherin Rabbit Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ve+cadherin/CDH5+Antibody/10__2147_slash_ijn__s618525-140-14-17
    Average 96 stars, based on 1 article reviews
    anti ve cadherin rabbit antibody - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology antibody against ve cadherin sc 9989
    circIdh2 attenuated TGF‐ β 1–induced EndMT changes in rEPCs. rEPCs were treated with or without TGF‐ β 1 (5 ng/mL) for 7 days, and then transfected with PCDH‐NC or PCDH‐circIdh2. (A) qRT‐PCR analysis of circIdh2 expression after transfection for 24 h. (B) Western blot analysis of EndMT‐related proteins <t>(VE‐cadherin,</t> vimentin, and N‐cadherin) after transfection for 48 h. (C) Transwell assay was performed to assess cell migration after transfection for 24 h. (D) Representative scratch wound healing images at 0, 24, and 48 h. Scale bars, 200 μ m. (E) Quantification of relative wound width (% of PCDH‐NC at 0 h). Data are mean ± SD; n = 3 independent biological experiments; one‐way ANOVA; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.
    Antibody Against Ve Cadherin Sc 9989, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ve+cadherin/VE-cadherin+Antibody/pm42785485-48-0-7
    Average 96 stars, based on 1 article reviews
    antibody against ve cadherin sc 9989 - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology anti ve cadherin a0734
    circIdh2 attenuated TGF‐ β 1–induced EndMT changes in rEPCs. rEPCs were treated with or without TGF‐ β 1 (5 ng/mL) for 7 days, and then transfected with PCDH‐NC or PCDH‐circIdh2. (A) qRT‐PCR analysis of circIdh2 expression after transfection for 24 h. (B) Western blot analysis of EndMT‐related proteins <t>(VE‐cadherin,</t> vimentin, and N‐cadherin) after transfection for 48 h. (C) Transwell assay was performed to assess cell migration after transfection for 24 h. (D) Representative scratch wound healing images at 0, 24, and 48 h. Scale bars, 200 μ m. (E) Quantification of relative wound width (% of PCDH‐NC at 0 h). Data are mean ± SD; n = 3 independent biological experiments; one‐way ANOVA; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.
    Anti Ve Cadherin A0734, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ve+cadherin/VE+Cadherin+Rabbit+pAb/pmc13525964-35-23-29
    Average 94 stars, based on 1 article reviews
    anti ve cadherin a0734 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    93
    R&D Systems mouse anti vecadherin
    circIdh2 attenuated TGF‐ β 1–induced EndMT changes in rEPCs. rEPCs were treated with or without TGF‐ β 1 (5 ng/mL) for 7 days, and then transfected with PCDH‐NC or PCDH‐circIdh2. (A) qRT‐PCR analysis of circIdh2 expression after transfection for 24 h. (B) Western blot analysis of EndMT‐related proteins <t>(VE‐cadherin,</t> vimentin, and N‐cadherin) after transfection for 48 h. (C) Transwell assay was performed to assess cell migration after transfection for 24 h. (D) Representative scratch wound healing images at 0, 24, and 48 h. Scale bars, 200 μ m. (E) Quantification of relative wound width (% of PCDH‐NC at 0 h). Data are mean ± SD; n = 3 independent biological experiments; one‐way ANOVA; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.
    Mouse Anti Vecadherin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ve+cadherin/Human+VE-Cadherin+Antibody/10__1096_slash_fj__202600727r-78-28-33
    Average 93 stars, based on 1 article reviews
    mouse anti vecadherin - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec cd144 (ve-cadherin) antibody, anti-human, reafinity
    circIdh2 attenuated TGF‐ β 1–induced EndMT changes in rEPCs. rEPCs were treated with or without TGF‐ β 1 (5 ng/mL) for 7 days, and then transfected with PCDH‐NC or PCDH‐circIdh2. (A) qRT‐PCR analysis of circIdh2 expression after transfection for 24 h. (B) Western blot analysis of EndMT‐related proteins <t>(VE‐cadherin,</t> vimentin, and N‐cadherin) after transfection for 48 h. (C) Transwell assay was performed to assess cell migration after transfection for 24 h. (D) Representative scratch wound healing images at 0, 24, and 48 h. Scale bars, 200 μ m. (E) Quantification of relative wound width (% of PCDH‐NC at 0 h). Data are mean ± SD; n = 3 independent biological experiments; one‐way ANOVA; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.
    Cd144 (Ve Cadherin) Antibody, Anti Human, Reafinity, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ve+cadherin/CD144+(VE-Cadherin)+Antibody%2C+anti-human%2C+REAfinity/custom%40130-135-356%4041168363
    Average 94 stars, based on 1 article reviews
    cd144 (ve-cadherin) antibody, anti-human, reafinity - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology ve cadherin
    circIdh2 attenuated TGF‐ β 1–induced EndMT changes in rEPCs. rEPCs were treated with or without TGF‐ β 1 (5 ng/mL) for 7 days, and then transfected with PCDH‐NC or PCDH‐circIdh2. (A) qRT‐PCR analysis of circIdh2 expression after transfection for 24 h. (B) Western blot analysis of EndMT‐related proteins <t>(VE‐cadherin,</t> vimentin, and N‐cadherin) after transfection for 48 h. (C) Transwell assay was performed to assess cell migration after transfection for 24 h. (D) Representative scratch wound healing images at 0, 24, and 48 h. Scale bars, 200 μ m. (E) Quantification of relative wound width (% of PCDH‐NC at 0 h). Data are mean ± SD; n = 3 independent biological experiments; one‐way ANOVA; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.
    Ve Cadherin, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ve+cadherin/CDH5+Rabbit+pAb/pm42209461-78-0-27
    Average 94 stars, based on 1 article reviews
    ve cadherin - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    Image Search Results


    circIdh2 attenuated TGF‐ β 1–induced EndMT changes in rEPCs. rEPCs were treated with or without TGF‐ β 1 (5 ng/mL) for 7 days, and then transfected with PCDH‐NC or PCDH‐circIdh2. (A) qRT‐PCR analysis of circIdh2 expression after transfection for 24 h. (B) Western blot analysis of EndMT‐related proteins (VE‐cadherin, vimentin, and N‐cadherin) after transfection for 48 h. (C) Transwell assay was performed to assess cell migration after transfection for 24 h. (D) Representative scratch wound healing images at 0, 24, and 48 h. Scale bars, 200 μ m. (E) Quantification of relative wound width (% of PCDH‐NC at 0 h). Data are mean ± SD; n = 3 independent biological experiments; one‐way ANOVA; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

    Journal: Cardiovascular Therapeutics

    Article Title: CircIdh2 Attenuates Endothelial‐to‐Mesenchymal Transition and Myocardial Fibrosis and Exhibits Translational Potential

    doi: 10.1155/cdr/2005876

    Figure Lengend Snippet: circIdh2 attenuated TGF‐ β 1–induced EndMT changes in rEPCs. rEPCs were treated with or without TGF‐ β 1 (5 ng/mL) for 7 days, and then transfected with PCDH‐NC or PCDH‐circIdh2. (A) qRT‐PCR analysis of circIdh2 expression after transfection for 24 h. (B) Western blot analysis of EndMT‐related proteins (VE‐cadherin, vimentin, and N‐cadherin) after transfection for 48 h. (C) Transwell assay was performed to assess cell migration after transfection for 24 h. (D) Representative scratch wound healing images at 0, 24, and 48 h. Scale bars, 200 μ m. (E) Quantification of relative wound width (% of PCDH‐NC at 0 h). Data are mean ± SD; n = 3 independent biological experiments; one‐way ANOVA; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

    Article Snippet: The primary antibodies used were as follows: VE‐cadherin (1:1000, #27956‐1‐AP, Proteintech, Wuhan, China), vimentin (1:1000, #ap2739b, Abcepta, Jiangsu, China), N‐cadherin (1:5000, #22018‐1‐AP, Proteintech), FLAG (1:2000, #20543‐1‐AP, Proteintech), and GAPDH (1:50000, #60004‐1‐Ig, Proteintech).

    Techniques: Transfection, Quantitative RT-PCR, Analysis, Expressing, Western Blot, Transwell Assay, Migration

    Knockdown of circIdh2 promoted EndMT changes in rEPCs. rEPCs were transfected with si‐NC or siRNAs targeting circIdh2. (A) qRT‐PCR analysis of circIdh2 expression after transfection for 24 h. (B) Western blot analysis of EndMT‐related proteins (VE‐cadherin, vimentin, and N‐cadherin) after transfection for 48 h. (C) Cell migration was assessed using a Transwell assay after transfection for 24 h. (D) Representative scratch wound healing images were obtained at 0, 24, and 48 h. Scale bars, 200 μ m. (E) Quantification of relative wound width (% of si‐NC at 0 h). Data are mean ± SD; n = 3 independent biological experiments; Student′s t ‐test was used for two‐group comparisons and one‐way ANOVA for multiple‐group comparisons; ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

    Journal: Cardiovascular Therapeutics

    Article Title: CircIdh2 Attenuates Endothelial‐to‐Mesenchymal Transition and Myocardial Fibrosis and Exhibits Translational Potential

    doi: 10.1155/cdr/2005876

    Figure Lengend Snippet: Knockdown of circIdh2 promoted EndMT changes in rEPCs. rEPCs were transfected with si‐NC or siRNAs targeting circIdh2. (A) qRT‐PCR analysis of circIdh2 expression after transfection for 24 h. (B) Western blot analysis of EndMT‐related proteins (VE‐cadherin, vimentin, and N‐cadherin) after transfection for 48 h. (C) Cell migration was assessed using a Transwell assay after transfection for 24 h. (D) Representative scratch wound healing images were obtained at 0, 24, and 48 h. Scale bars, 200 μ m. (E) Quantification of relative wound width (% of si‐NC at 0 h). Data are mean ± SD; n = 3 independent biological experiments; Student′s t ‐test was used for two‐group comparisons and one‐way ANOVA for multiple‐group comparisons; ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

    Article Snippet: The primary antibodies used were as follows: VE‐cadherin (1:1000, #27956‐1‐AP, Proteintech, Wuhan, China), vimentin (1:1000, #ap2739b, Abcepta, Jiangsu, China), N‐cadherin (1:5000, #22018‐1‐AP, Proteintech), FLAG (1:2000, #20543‐1‐AP, Proteintech), and GAPDH (1:50000, #60004‐1‐Ig, Proteintech).

    Techniques: Knockdown, Transfection, Quantitative RT-PCR, Analysis, Expressing, Western Blot, Migration, Transwell Assay

    The FLAG‐tagged circIdh2 construct affected EndMT‐related markers and cell migration in rEPCs. rEPCs were transfected with PCDH‐NC or PCDH‐flag‐circIdh2. (A) qRT‐PCR analysis of circIdh2 expression after transfection for 24 h. (B) Western blot analysis of FLAG expression after transfection for 48 h. (C) Western blot analysis of EndMT‐related proteins (VE‐cadherin, vimentin, and N‐cadherin) after transfection for 48 h. (D) Cell migration was examined by Transwell assay after transfection for 24 h. (E) Representative images from the scratch wound healing assay at 0, 24, and 48 h. Scale bar, 200 μ m. (F) Quantification of relative wound width (% of PCDH‐NC at 0 h). Data are mean ± SD; n = 3 independent biological experiments; unpaired Student′s t ‐test; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

    Journal: Cardiovascular Therapeutics

    Article Title: CircIdh2 Attenuates Endothelial‐to‐Mesenchymal Transition and Myocardial Fibrosis and Exhibits Translational Potential

    doi: 10.1155/cdr/2005876

    Figure Lengend Snippet: The FLAG‐tagged circIdh2 construct affected EndMT‐related markers and cell migration in rEPCs. rEPCs were transfected with PCDH‐NC or PCDH‐flag‐circIdh2. (A) qRT‐PCR analysis of circIdh2 expression after transfection for 24 h. (B) Western blot analysis of FLAG expression after transfection for 48 h. (C) Western blot analysis of EndMT‐related proteins (VE‐cadherin, vimentin, and N‐cadherin) after transfection for 48 h. (D) Cell migration was examined by Transwell assay after transfection for 24 h. (E) Representative images from the scratch wound healing assay at 0, 24, and 48 h. Scale bar, 200 μ m. (F) Quantification of relative wound width (% of PCDH‐NC at 0 h). Data are mean ± SD; n = 3 independent biological experiments; unpaired Student′s t ‐test; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

    Article Snippet: The primary antibodies used were as follows: VE‐cadherin (1:1000, #27956‐1‐AP, Proteintech, Wuhan, China), vimentin (1:1000, #ap2739b, Abcepta, Jiangsu, China), N‐cadherin (1:5000, #22018‐1‐AP, Proteintech), FLAG (1:2000, #20543‐1‐AP, Proteintech), and GAPDH (1:50000, #60004‐1‐Ig, Proteintech).

    Techniques: Construct, Migration, Transfection, Quantitative RT-PCR, Analysis, Expressing, Western Blot, Transwell Assay, Wound Healing Assay

    The circIdh2 mutant did not reproduce the effects of wild‐type circIdh2 on EndMT‐related markers and cell migration. rEPCs were transfected with PCDH‐NC, PCDH‐circIdh2, or PCDH‐circIdh2‐mut. (A) Western blot analysis of EndMT‐related proteins (VE‐cadherin, vimentin, and N‐cadherin) after transfection for 48 h. (B) Cell migration was assessed using a Transwell assay after transfection for 24 h. (C) Representative scratch wound healing images at 0, 24, and 48 h, with quantification of relative wound width (% of PCDH‐NC at 0 h). Scale bar, 200 μ m. Data are mean ± SD; n = 3 independent biological experiments; one‐way ANOVA; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

    Journal: Cardiovascular Therapeutics

    Article Title: CircIdh2 Attenuates Endothelial‐to‐Mesenchymal Transition and Myocardial Fibrosis and Exhibits Translational Potential

    doi: 10.1155/cdr/2005876

    Figure Lengend Snippet: The circIdh2 mutant did not reproduce the effects of wild‐type circIdh2 on EndMT‐related markers and cell migration. rEPCs were transfected with PCDH‐NC, PCDH‐circIdh2, or PCDH‐circIdh2‐mut. (A) Western blot analysis of EndMT‐related proteins (VE‐cadherin, vimentin, and N‐cadherin) after transfection for 48 h. (B) Cell migration was assessed using a Transwell assay after transfection for 24 h. (C) Representative scratch wound healing images at 0, 24, and 48 h, with quantification of relative wound width (% of PCDH‐NC at 0 h). Scale bar, 200 μ m. Data are mean ± SD; n = 3 independent biological experiments; one‐way ANOVA; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

    Article Snippet: The primary antibodies used were as follows: VE‐cadherin (1:1000, #27956‐1‐AP, Proteintech, Wuhan, China), vimentin (1:1000, #ap2739b, Abcepta, Jiangsu, China), N‐cadherin (1:5000, #22018‐1‐AP, Proteintech), FLAG (1:2000, #20543‐1‐AP, Proteintech), and GAPDH (1:50000, #60004‐1‐Ig, Proteintech).

    Techniques: Mutagenesis, Migration, Transfection, Western Blot, Analysis, Transwell Assay

    AAV‐mediated delivery of circIdh2 or circIdh2‐aa attenuated myocardial fibrosis and EndMT‐related marker changes in vivo. (A) HE staining of myocardial infarction tissues from the sham, model, circIdh2‐AAV, and circIdh2‐aa‐AAV groups. (B) Masson staining of MI tissues. (C) IF detection and quantification of fibrotic markers (Collagen I and TGF‐ β ) in myocardial tissues. Scale bars, 100 μ m. (D) Western blot analysis of EndMT‐related proteins (VE‐cadherin, vimentin, and N‐cadherin). Data are mean ± SD; n = 3 rats per group; one‐way ANOVA; ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

    Journal: Cardiovascular Therapeutics

    Article Title: CircIdh2 Attenuates Endothelial‐to‐Mesenchymal Transition and Myocardial Fibrosis and Exhibits Translational Potential

    doi: 10.1155/cdr/2005876

    Figure Lengend Snippet: AAV‐mediated delivery of circIdh2 or circIdh2‐aa attenuated myocardial fibrosis and EndMT‐related marker changes in vivo. (A) HE staining of myocardial infarction tissues from the sham, model, circIdh2‐AAV, and circIdh2‐aa‐AAV groups. (B) Masson staining of MI tissues. (C) IF detection and quantification of fibrotic markers (Collagen I and TGF‐ β ) in myocardial tissues. Scale bars, 100 μ m. (D) Western blot analysis of EndMT‐related proteins (VE‐cadherin, vimentin, and N‐cadherin). Data are mean ± SD; n = 3 rats per group; one‐way ANOVA; ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

    Article Snippet: The primary antibodies used were as follows: VE‐cadherin (1:1000, #27956‐1‐AP, Proteintech, Wuhan, China), vimentin (1:1000, #ap2739b, Abcepta, Jiangsu, China), N‐cadherin (1:5000, #22018‐1‐AP, Proteintech), FLAG (1:2000, #20543‐1‐AP, Proteintech), and GAPDH (1:50000, #60004‐1‐Ig, Proteintech).

    Techniques: Marker, In Vivo, H&E Stain, Staining, Western Blot, Analysis